{"id":935627,"date":"2026-02-10T10:00:47","date_gmt":"2026-02-10T15:00:47","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/creative-medical-technology-holdings-achieves-second-who-inn-milestone-strengthening-global-regulatory-positioning-across-expanding-cell-therapy-pipeline\/"},"modified":"2026-02-10T10:00:47","modified_gmt":"2026-02-10T15:00:47","slug":"creative-medical-technology-holdings-achieves-second-who-inn-milestone-strengthening-global-regulatory-positioning-across-expanding-cell-therapy-pipeline","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/creative-medical-technology-holdings-achieves-second-who-inn-milestone-strengthening-global-regulatory-positioning-across-expanding-cell-therapy-pipeline\/","title":{"rendered":"Creative Medical Technology Holdings Achieves Second WHO INN Milestone, Strengthening Global Regulatory Positioning Across Expanding Cell Therapy Pipeline"},"content":{"rendered":"<h2>\nWHO recognition of \u201cetaroleucel\u201d (CELZ-101) builds on prior \u201colastrocel\u201d (CELZ-201) milestone, reinforcing platform credibility and supporting multi-program execution<br \/>\n<\/h2>\n<div class=\"mw_release\">\n<p align=\"justify\">PHOENIX, Feb.  10, 2026  (GLOBE NEWSWIRE) &#8212; <strong>Creative Medical Technology Holdings, Inc. (NASDAQ: CELZ) (\u201cCreative Medical\u201d or the \u201cCompany\u201d)<\/strong>, a regenerative medicine company advancing disruptive cell-based therapies for high-unmet-need indications, today announced the achievement of its second International Nonproprietary Name (INN) milestone with the World Health Organization (WHO), marking continued regulatory progress across its expanding clinical pipeline. INNs are assigned by the WHO to uniquely and universally identify pharmaceutical substances and biologics worldwide.<\/p>\n<p align=\"justify\">The WHO has published the proposed INN \u201cetaroleucel\u201d for CELZ-101, the Company\u2019s autologous regulatory T-cell (Treg) immunotherapy program, in Proposed INN List 134, following expert review during the 80th WHO INN Consultation (March 18\u201321, 2025). As part of the standard WHO process, the name is now entering the formal objection period prior to final confirmation.<\/p>\n<p align=\"justify\">CELZ-101 (etaroleucel) is designed to induce immune tolerance in complex autoimmune settings, including Type 1 diabetes in the context of pancreatic islet transplantation. The CELZ-101 platform has also been validated in cardiovascular and hepatic clinical applications.<\/p>\n<p align=\"justify\">This achievement follows WHO approval of \u201colastrocel\u201d as the INN for the active cellular substance in CELZ-201, the Company\u2019s lead allogeneic cell therapy also known as AlloStem\u00ae. This name was reviewed during the 79th WHO INN Consultation (October 22\u201325, 2024) and published in Proposed INN List 133, underscoring Creative Medical\u2019s ability to advance multiple, distinct cell therapy programs through internationally recognized regulatory frameworks.<\/p>\n<p align=\"justify\">CELZ-201 (olastrocel) is being developed for chronic lower back pain and degenerative disc disease.<\/p>\n<p>\n        <strong>CEO Commentary<br \/><\/strong>\u201cAchieving proposed INN status for a second independent clinical program is a powerful validation of both our science and our regulatory execution,\u201d said Timothy Warbington, President and CEO of Creative Medical. \u201cVery few emerging regenerative medicine companies successfully advance multiple platforms through the WHO INN process. The recognition of both olastrocel and etaroleucel highlights the differentiation of our technologies and reflects the growing maturity of our pipeline.\u201d<\/p>\n<p align=\"justify\">Warbington continued: \u201cThese milestones are not symbolic \u2014 they are foundational. INN recognition is essential for global clinical development, regulatory alignment, and eventual commercialization. We believe Creative Medical is building a scalable, internationally credible platform positioned for long-term value creation.\u201d<\/p>\n<p>\n        <strong>Momentum Across the Pipeline<\/strong><br \/>\n        <br \/>With both programs advancing through internationally recognized regulatory pathways, Creative Medical continues to execute on its strategy to translate innovative cell technologies.<\/p>\n<p>\n        <strong>About Creative Medical Technology Holdings, Inc.<br \/><\/strong>Creative Medical Technology Holdings, Inc. (NASDAQ: CELZ) is a clinical-stage biotechnology company pioneering regenerative medicine therapies derived from adult and perinatal stem cell technologies. The Company\u2019s pipeline targets large, underserved markets across orthopedics, immunotherapy, endocrinology, urology, and gynecology, with a mission to deliver scalable, disease-modifying solutions for patients with high unmet medical needs.<\/p>\n<p>For more information, visit <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=q1JIh8fNUWrFuP8YYaLgeqCZXnsna6osXB8swsmRrizr7KF0aJwMRF1HOvAVE-GLB-h1TZzGdkQtFD6hpd8OZLuseOVv2_9IGKJCWvkyMJFUSRA5sbzUeTePOSaRsn8Zt4z5KVmrclgjLgKabyOmvg==\" rel=\"nofollow\" target=\"_blank\">www.creativemedicaltechnology.com<\/a><\/p>\n<p>\n        <strong>Forward-Looking Statements<br \/><\/strong>This press release contains forward-looking statements regarding clinical development, regulatory strategy and positioning, commercialization potential, and market opportunity. These statements are based on current expectations and involve risks and uncertainties that could cause actual results to differ materially. Factors include clinical trial outcomes, regulatory decisions, manufacturing considerations, competitive dynamics, and market conditions. Please refer to the Company\u2019s filings with the SEC for a discussion of these risks. The Company undertakes no obligation to update forward-looking statements except as required by law.<\/p>\n<p>\n        <strong>Investor &amp; Media Contacts<\/strong><br \/>\n        <br \/>\n        <strong>Creative Medical Technology Holdings, Inc.<\/strong><br \/>\n        <br \/>IR@CreativeMedicalTechnology.com<br \/><a href=\"https:\/\/www.globenewswire.com\/Tracker?data=q1JIh8fNUWrFuP8YYaLgeqCZXnsna6osXB8swsmRriw6u7RFJVPcXvMiK0x9DZVaUTFXsqbPFyWnUnLA8PSE4tTWJBpZoij49_GhiAJXrbl15REa9RqNW7vBuytvqZjYTVJfSP-qUnkr7JXl57VRRg==\" rel=\"nofollow\" target=\"_blank\">www.creativemedicaltechnology.com<\/a><\/p>\n<p>\n        <strong>Investor Relations<\/strong><br \/>\n        <br \/>Devin Sullivan \u2014 The Equity Group Inc.<br \/><a href=\"https:\/\/www.globenewswire.com\/Tracker?data=FQv5MgIBza-G15I8Qqp0OADTSFq46iOnFKBQOrsx_N8Snx0jR99iFJsqniEXMvb08V_9xM--cIswUYJm06nL_8TiCMDKQ5NcoZe5XLyMosSQSFLzYAJwXE7KKOcRiGy1\" rel=\"nofollow\" target=\"_blank\">dsullivan@theequitygroup.com<\/a><\/p>\n<p>Conor Rodriguez \u2014 The Equity Group Inc.<br \/><a href=\"https:\/\/www.globenewswire.com\/Tracker?data=CL-ddOZiCQT5tMLAqLrYoDRz8HXQaoST_ylfvJG0Yy_2UOZgIKhIGeJvgJqiEEK-nZ6cFGPmVzQvSDWvl8ORd5J4KuyetSSotHUohIuigzh6lubXKSDcanzAhcvFPjPd\" rel=\"nofollow\" target=\"_blank\">crodriguez@theequitygroup.com<\/a><\/p>\n<p>\n        <strong>RedChip Companies<\/strong><br \/>\n        <br \/>Dave Gentry \u2014 <strong>CELZ@redchip.com<\/strong> | 1-407-644-4256<br \/>Paul Kuntz \u2014 <strong>paul@redchip.com<\/strong> | 412-708-4590<\/p>\n<p>      <img decoding=\"async\" alt=\"\" class=\"__GNW8366DE3E__IMG\" src=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTY1MTYxMSM3NDE3NDE4IzIwOTYxNzQ=\" \/><br \/>\n      <br \/>\n      <img decoding=\"async\" alt=\"\" src=\"https:\/\/ml.globenewswire.com\/media\/NThiNzA4MDMtYzgyNy00OTllLWE3OTgtMmIzZGY3OWU0M2RiLTExMDc3NDUtMjAyNi0wMi0xMC1lbg==\/tiny\/Creative-Medical-Technology-Ho.png\" \/>\n    <\/div>\n<div class=\"mw_contactinfo\"><\/div>\n","protected":false},"excerpt":{"rendered":"<p>WHO recognition of \u201cetaroleucel\u201d (CELZ-101) builds on prior \u201colastrocel\u201d (CELZ-201) milestone, reinforcing platform credibility and supporting multi-program execution PHOENIX, Feb. 10, 2026 (GLOBE NEWSWIRE) &#8212; Creative Medical Technology Holdings, Inc. (NASDAQ: CELZ) (\u201cCreative Medical\u201d or the \u201cCompany\u201d), a regenerative medicine company advancing disruptive cell-based therapies for high-unmet-need indications, today announced the achievement of its second International Nonproprietary Name (INN) milestone with the World Health Organization (WHO), marking continued regulatory progress across its expanding clinical pipeline. INNs are assigned by the WHO to uniquely and universally identify pharmaceutical substances and biologics worldwide. The WHO has published the proposed INN \u201cetaroleucel\u201d for CELZ-101, the Company\u2019s autologous regulatory T-cell (Treg) immunotherapy program, in Proposed INN List 134, following expert review during the 80th &hellip; <\/p>\n<p class=\"link-more\"><a href=\"https:\/\/www.marketnewsdesk.com\/index.php\/creative-medical-technology-holdings-achieves-second-who-inn-milestone-strengthening-global-regulatory-positioning-across-expanding-cell-therapy-pipeline\/\" class=\"more-link\">Continue reading<span class=\"screen-reader-text\"> &#8220;Creative Medical Technology Holdings Achieves Second WHO INN Milestone, Strengthening Global Regulatory Positioning Across Expanding Cell Therapy Pipeline&#8221;<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-935627","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.6 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Creative Medical Technology Holdings Achieves Second WHO INN Milestone, Strengthening Global Regulatory Positioning Across Expanding Cell Therapy Pipeline - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/creative-medical-technology-holdings-achieves-second-who-inn-milestone-strengthening-global-regulatory-positioning-across-expanding-cell-therapy-pipeline\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Creative Medical Technology Holdings Achieves Second WHO INN Milestone, Strengthening Global Regulatory Positioning Across Expanding Cell Therapy Pipeline - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"WHO recognition of \u201cetaroleucel\u201d (CELZ-101) builds on prior \u201colastrocel\u201d (CELZ-201) milestone, reinforcing platform credibility and supporting multi-program execution PHOENIX, Feb. 10, 2026 (GLOBE NEWSWIRE) &#8212; Creative Medical Technology Holdings, Inc. (NASDAQ: CELZ) (\u201cCreative Medical\u201d or the \u201cCompany\u201d), a regenerative medicine company advancing disruptive cell-based therapies for high-unmet-need indications, today announced the achievement of its second International Nonproprietary Name (INN) milestone with the World Health Organization (WHO), marking continued regulatory progress across its expanding clinical pipeline. INNs are assigned by the WHO to uniquely and universally identify pharmaceutical substances and biologics worldwide. The WHO has published the proposed INN \u201cetaroleucel\u201d for CELZ-101, the Company\u2019s autologous regulatory T-cell (Treg) immunotherapy program, in Proposed INN List 134, following expert review during the 80th &hellip; Continue reading &quot;Creative Medical Technology Holdings Achieves Second WHO INN Milestone, Strengthening Global Regulatory Positioning Across Expanding Cell Therapy Pipeline&quot;\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/creative-medical-technology-holdings-achieves-second-who-inn-milestone-strengthening-global-regulatory-positioning-across-expanding-cell-therapy-pipeline\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2026-02-10T15:00:47+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTY1MTYxMSM3NDE3NDE4IzIwOTYxNzQ=\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"3 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/creative-medical-technology-holdings-achieves-second-who-inn-milestone-strengthening-global-regulatory-positioning-across-expanding-cell-therapy-pipeline\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/creative-medical-technology-holdings-achieves-second-who-inn-milestone-strengthening-global-regulatory-positioning-across-expanding-cell-therapy-pipeline\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"Creative Medical Technology Holdings Achieves Second WHO INN Milestone, Strengthening Global Regulatory Positioning Across Expanding Cell Therapy Pipeline\",\"datePublished\":\"2026-02-10T15:00:47+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/creative-medical-technology-holdings-achieves-second-who-inn-milestone-strengthening-global-regulatory-positioning-across-expanding-cell-therapy-pipeline\\\/\"},\"wordCount\":608,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/creative-medical-technology-holdings-achieves-second-who-inn-milestone-strengthening-global-regulatory-positioning-across-expanding-cell-therapy-pipeline\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTY1MTYxMSM3NDE3NDE4IzIwOTYxNzQ=\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/creative-medical-technology-holdings-achieves-second-who-inn-milestone-strengthening-global-regulatory-positioning-across-expanding-cell-therapy-pipeline\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/creative-medical-technology-holdings-achieves-second-who-inn-milestone-strengthening-global-regulatory-positioning-across-expanding-cell-therapy-pipeline\\\/\",\"name\":\"Creative Medical Technology Holdings Achieves Second WHO INN Milestone, Strengthening Global Regulatory Positioning Across Expanding Cell Therapy Pipeline - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/creative-medical-technology-holdings-achieves-second-who-inn-milestone-strengthening-global-regulatory-positioning-across-expanding-cell-therapy-pipeline\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/creative-medical-technology-holdings-achieves-second-who-inn-milestone-strengthening-global-regulatory-positioning-across-expanding-cell-therapy-pipeline\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTY1MTYxMSM3NDE3NDE4IzIwOTYxNzQ=\",\"datePublished\":\"2026-02-10T15:00:47+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/creative-medical-technology-holdings-achieves-second-who-inn-milestone-strengthening-global-regulatory-positioning-across-expanding-cell-therapy-pipeline\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/creative-medical-technology-holdings-achieves-second-who-inn-milestone-strengthening-global-regulatory-positioning-across-expanding-cell-therapy-pipeline\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/creative-medical-technology-holdings-achieves-second-who-inn-milestone-strengthening-global-regulatory-positioning-across-expanding-cell-therapy-pipeline\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTY1MTYxMSM3NDE3NDE4IzIwOTYxNzQ=\",\"contentUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTY1MTYxMSM3NDE3NDE4IzIwOTYxNzQ=\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/creative-medical-technology-holdings-achieves-second-who-inn-milestone-strengthening-global-regulatory-positioning-across-expanding-cell-therapy-pipeline\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Creative Medical Technology Holdings Achieves Second WHO INN Milestone, Strengthening Global Regulatory Positioning Across Expanding Cell Therapy Pipeline\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Creative Medical Technology Holdings Achieves Second WHO INN Milestone, Strengthening Global Regulatory Positioning Across Expanding Cell Therapy Pipeline - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/creative-medical-technology-holdings-achieves-second-who-inn-milestone-strengthening-global-regulatory-positioning-across-expanding-cell-therapy-pipeline\/","og_locale":"en_US","og_type":"article","og_title":"Creative Medical Technology Holdings Achieves Second WHO INN Milestone, Strengthening Global Regulatory Positioning Across Expanding Cell Therapy Pipeline - Market Newsdesk","og_description":"WHO recognition of \u201cetaroleucel\u201d (CELZ-101) builds on prior \u201colastrocel\u201d (CELZ-201) milestone, reinforcing platform credibility and supporting multi-program execution PHOENIX, Feb. 10, 2026 (GLOBE NEWSWIRE) &#8212; Creative Medical Technology Holdings, Inc. (NASDAQ: CELZ) (\u201cCreative Medical\u201d or the \u201cCompany\u201d), a regenerative medicine company advancing disruptive cell-based therapies for high-unmet-need indications, today announced the achievement of its second International Nonproprietary Name (INN) milestone with the World Health Organization (WHO), marking continued regulatory progress across its expanding clinical pipeline. INNs are assigned by the WHO to uniquely and universally identify pharmaceutical substances and biologics worldwide. The WHO has published the proposed INN \u201cetaroleucel\u201d for CELZ-101, the Company\u2019s autologous regulatory T-cell (Treg) immunotherapy program, in Proposed INN List 134, following expert review during the 80th &hellip; Continue reading \"Creative Medical Technology Holdings Achieves Second WHO INN Milestone, Strengthening Global Regulatory Positioning Across Expanding Cell Therapy Pipeline\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/creative-medical-technology-holdings-achieves-second-who-inn-milestone-strengthening-global-regulatory-positioning-across-expanding-cell-therapy-pipeline\/","og_site_name":"Market Newsdesk","article_published_time":"2026-02-10T15:00:47+00:00","og_image":[{"url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTY1MTYxMSM3NDE3NDE4IzIwOTYxNzQ=","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"3 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/creative-medical-technology-holdings-achieves-second-who-inn-milestone-strengthening-global-regulatory-positioning-across-expanding-cell-therapy-pipeline\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/creative-medical-technology-holdings-achieves-second-who-inn-milestone-strengthening-global-regulatory-positioning-across-expanding-cell-therapy-pipeline\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"Creative Medical Technology Holdings Achieves Second WHO INN Milestone, Strengthening Global Regulatory Positioning Across Expanding Cell Therapy Pipeline","datePublished":"2026-02-10T15:00:47+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/creative-medical-technology-holdings-achieves-second-who-inn-milestone-strengthening-global-regulatory-positioning-across-expanding-cell-therapy-pipeline\/"},"wordCount":608,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/creative-medical-technology-holdings-achieves-second-who-inn-milestone-strengthening-global-regulatory-positioning-across-expanding-cell-therapy-pipeline\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTY1MTYxMSM3NDE3NDE4IzIwOTYxNzQ=","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/creative-medical-technology-holdings-achieves-second-who-inn-milestone-strengthening-global-regulatory-positioning-across-expanding-cell-therapy-pipeline\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/creative-medical-technology-holdings-achieves-second-who-inn-milestone-strengthening-global-regulatory-positioning-across-expanding-cell-therapy-pipeline\/","name":"Creative Medical Technology Holdings Achieves Second WHO INN Milestone, Strengthening Global Regulatory Positioning Across Expanding Cell Therapy Pipeline - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/creative-medical-technology-holdings-achieves-second-who-inn-milestone-strengthening-global-regulatory-positioning-across-expanding-cell-therapy-pipeline\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/creative-medical-technology-holdings-achieves-second-who-inn-milestone-strengthening-global-regulatory-positioning-across-expanding-cell-therapy-pipeline\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTY1MTYxMSM3NDE3NDE4IzIwOTYxNzQ=","datePublished":"2026-02-10T15:00:47+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/creative-medical-technology-holdings-achieves-second-who-inn-milestone-strengthening-global-regulatory-positioning-across-expanding-cell-therapy-pipeline\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/creative-medical-technology-holdings-achieves-second-who-inn-milestone-strengthening-global-regulatory-positioning-across-expanding-cell-therapy-pipeline\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/creative-medical-technology-holdings-achieves-second-who-inn-milestone-strengthening-global-regulatory-positioning-across-expanding-cell-therapy-pipeline\/#primaryimage","url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTY1MTYxMSM3NDE3NDE4IzIwOTYxNzQ=","contentUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTY1MTYxMSM3NDE3NDE4IzIwOTYxNzQ="},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/creative-medical-technology-holdings-achieves-second-who-inn-milestone-strengthening-global-regulatory-positioning-across-expanding-cell-therapy-pipeline\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"Creative Medical Technology Holdings Achieves Second WHO INN Milestone, Strengthening Global Regulatory Positioning Across Expanding Cell Therapy Pipeline"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/935627","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=935627"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/935627\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=935627"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=935627"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=935627"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}